Coinciding functions for miR-145 in vascular smooth muscle and cardiac fibroblasts

Journal of Molecular and Cellular Cardiology

Volumn 65, Issue , 2013, Pages 105-107

  Engelhardt, Stefan ^a,b   Leierseder, Simon ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 5; MICRORNA 145; TRANSFORMING GROWTH FACTOR BETA;

CARDIAC FIBROBLAST; CELL DIFFERENTIATION; CELL HYPOXIA; CELL TRANSFORMATION; CELL TYPE; EDITORIAL; EXTRACELLULAR MATRIX; FIBROBLAST; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; IN SITU HYBRIDIZATION; INTRACELLULAR SIGNALING; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN TARGETING; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; FIBROBLASTS; HUMANS; MICE; MICRORNAS; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; MYOCYTES, SMOOTH MUSCLE;

EID: 84886560127     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.10.002     Document Type: Editorial

References (28)

1. Kakkar R., Lee R.T. Intramyocardial fibroblast myocyte communication. Circ Res 2010, 106:47-57.
2. Vliegen H.W., van der Laarse A., Cornelisse C.J., Eulderink F. Myocardial changes in pressure overload-induced left ventricular hypertrophy. A study on tissue composition, polyploidization and multinucleation. Eur Heart J 1991, 12:488-494.
3. Souders C.A., Bowers S.L.K., Baudino T.A. Cardiac fibroblast: the renaissance cell. Circ Res 2009, 105:1164-1176.
4. Chen W., Frangogiannis N.G. Fibroblasts in post-infarction inflammation and cardiac repair. Biochim Biophys Acta 1833, 2013:945-953.
5. Takeda N., Manabe I., Uchino Y., Eguchi K., Matsumoto S., Nishimura S., et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 2010, 120:254-265.
6. Wynn T.A., Ramalingam T.R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012, 18:1028-1040.
7. Weidemann F., Herrmann S., Störk S., Niemann M., Frantz S., Lange V., et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009, 120:577-584.
8. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
9. Wakisaka O., Takahashi N., Shinohara T., Ooie T., Nakagawa M., Yonemochi H., et al. Hyperthermia treatment prevents angiotensin II-mediated atrial fibrosis and fibrillation via induction of heat-shock protein 72. J Mol Cell Cardiol 2007, 43:616-626.
10. Ju H., Zhao S., Jassal D.S., Dixon I.M. Effect of AT1 receptor blockade on cardiac collagen remodeling after myocardial infarction. Cardiovasc Res 1997, 35:223-232.
11. Hinz B., Phan S.H., Thannickal V.J., Prunotto M., Desmoulière A., Varga J., et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012, 180:1340-1355.
12. Jazbutyte V., Fiedler J., Kneitz S., Galuppo P., Just A., Holzmann A., et al. MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age (Dordr) 2013, 35:747-762.
13. Pan Z., Sun X., Shan H., Wang N., Wang J., Ren J., et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway. Circulation 2012, 126:840-850.
14. Van Rooij E., Sutherland L.B., Thatcher J.E., DiMaio J.M., Naseem R.H., Marshall W.S., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008, 105:13027-13032.
15. Dawson K., Wakili R., Ordög B., Clauss S., Chen Y., Iwasaki Y., et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 2013, 127:1466-1475. [1475e1-28].
16. Wang Y.-S., Li S.-H., Guo J., Mihic A., Wu J., Sun L., et al. Role of miR-145 in cardiac myofibroblast differentiation. J Mol Cell Cardiol 2013, 10.1016/j.yjmcc.2013.08.007.
17. Xin M., Small E.M., Sutherland L.B., Qi X., McAnally J., Plato C.F., et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009, 23:2166-2178.
18. Cordes K.R., Sheehy N.T., White M.P., Berry E.C., Morton S.U., Muth A.N., et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009, 460:705-710.
19. Cheng Y., Liu X., Yang J., Lin Y., Xu D.-Z., Lu Q., et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009, 105:158-166.
20. Boettger T., Beetz N., Kostin S., Schneider J., Krüger M., Hein L., et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009, 119:2634-2647.
21. Elia L., Quintavalle M., Zhang J., Contu R., Cossu L., Latronico M.V.G., et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 2009, 16:1590-1598.
22. Zhang C. MicroRNA-145 in vascular smooth muscle cell biology. Cell Cycle 2009, 8:3469-3473.
23. Hergenreider E., Heydt S., Tréguer K., Boettger T., Horrevoets A.J.G., Zeiher A.M., et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012, 14:249-256.
24. Lovren F., Pan Y., Quan A., Singh K.K., Shukla P.C., Gupta N., et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 2012, 126:S81-S90.
25. Hutcheson R., Terry R., Chaplin J., Smith E., Musiyenko A., Russell J.C., et al. MicroRNA-145 restores contractile vascular smooth muscle phenotype and coronary collateral growth in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2013, 33:727-736.
26. Yang S., Cui H., Xie N., Icyuz M., Banerjee S., Antony V.B., et al. miR-145 regulates myofibroblast differentiation and lung fibrosis. FASEB J 2013, 27:2382-2391.
27. Davis-Dusenbery B.N., Chan M.C., Reno K.E., Weisman A.S., Layne M.D., Lagna G., et al. Down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor- and bone morphogenetic protein 4. J Biol Chem 2011, 286:28097-110.
28. Long X., Miano J.M. Transforming growth factor-beta1 (TGF-beta1) utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells. J Biol Chem 2011, 286:30119-30129.